FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

	OMB Number:	3235-0287
	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BOGER JOSHUA S					V	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]											tionship o all applic Director	able)	g Pers	on(s) to Issu 10% Ow		
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET					3. [3. Date of Earliest Transaction (Month/Day/Year) 10/11/2005											X Officer (give title Other (specify below) below) Chairman, President & CEO					
(Street) CAMBR (City)			02139 (Zip)		4. l	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Lir		ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1			2. Transaction Date (Month/Day/Year)		ear) i	2A. Deemed Execution Date, if any (Month/Day/Year)		<i>'</i>	3. Transaction Code (Instr. 8)			ities Acquired (A) d Of (D) (Instr. 3, 4			and Securition Benefici Owned I		s Illy ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
										Code	v	Amount	(A) or P		Price		Reported Transacti (Instr. 3 a	ion(s)			Instr. 4)	
Common	Stock			10/11	1/2005					М		7,100		A	\$9.5		995	95,302		D		
Common Stock 10				10/11	1/2005					S ⁽¹⁾		7,100		D	\$21.12		988,202		D			
Common Stock																	207	,500			shares in rust ⁽²⁾	
Common Stock																10,	920		I	401(k)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transactior Code (Instr. 8)				6. Date Exercisal Expiration Date (Month/Day/Year				7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)			D S (II	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Da:	te ercisable		Expiration Date	Title		Amoun or Number of Shares							
Stock Option	\$9.5	10/11/2005			A			7,100	03/	/14/1996	(3) 1	2/13/2005		nmon ock	7,100		\$0	1,490,4	11	D		

Explanation of Responses:

- 1. Transaction made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.
- $2. \ Shares \ held \ in \ trust \ for \ Dr. \ Boger's \ children. \ Dr. \ Boger \ disclaims \ beneficial \ ownership \ of \ such \ shares.$
- 3. Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/95.

Remarks:

Valerie L. Andrews, Attorney-

10/12/2005

In-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.